Cellectis SA (CLLS)

Currency in USD
2.650
-0.020(-0.75%)
Real-time Data·
CLLS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 4 days
Fair Value
Day's Range
2.6102.730
52 wk Range
1.1003.100
Key Statistics
Prev. Close
2.67
Open
2.68
Day's Range
2.61-2.73
52 wk Range
1.1-3.1
Volume
18.89K
Average Volume (3m)
127.09K
1-Year Change
20.81%
Book Value / Share
1.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.750
Upside
+116.98%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Cellectis SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Cellectis SA Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Cellectis SA SWOT Analysis


Pipeline Progress
Explore Cellectis's advancements in CAR T therapies, with UCART22 and UCART20x22 programs showing promise in hematological cancers and lymphoma
Strategic Partnerships
Delve into Cellectis's collaborations with AstraZeneca, Servier, and Allogene, potentially unlocking billions in milestone payments and royalties
Financial Fortitude
Learn how Cellectis strengthened its cash position to $264 million, extending its runway to mid-2027 and supporting ongoing R&D efforts
Market Valuation
Analyst price targets range from $3 to $10, suggesting potential upside despite recent stock volatility and a 51% decline over the past yea
Read full SWOT analysis

Cellectis SA Earnings Call Summary for Q3/2024

  • Cash reserves increased to $264M, bolstered by $140M AstraZeneca investment and $47M collaboration funding
  • Three new R&D programs initiated with AstraZeneca, including two allogeneic CAR T therapies and an in vivo gene therapy
  • UCART123 program deprioritized; focus shifted to BALLI-01 study and other promising assets
  • Company aims to extend cash runway to 2027 through financial management and partnership milestones
  • Phase I data presentation planned for 2025; strong patient demand noted for UCART20x22 program
Last Updated: 06/11/2024, 20:10
Read Full Transcript

Compare CLLS to Peers and Sector

Metrics to compare
CLLS
Peers
Sector
Relationship
P/E Ratio
−3.2x−0.9x−0.5x
PEG Ratio
−0.06−0.050.00
Price/Book
1.7x2.7x2.6x
Price / LTM Sales
3.5x2.9x3.3x
Upside (Analyst Target)
89.4%30.4%42.4%
Fair Value Upside
Unlock29.0%7.2%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.750
(+116.98% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.17 / -0.24
Revenue / Forecast
12.00M / 11.96M
EPS Revisions
Last 90 days

CLLS Income Statement

People Also Watch

154.33
KRYS
+0.72%
21.42
TDC
-1.06%
11.9000
BSEM
+3.30%
25.66
CNC
-0.50%
29.61
YOU
-0.44%

FAQ

What Stock Exchange Does Cellectis Trade On?

Cellectis is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cellectis?

The stock symbol for Cellectis is "CLLS."

What Is the Cellectis Market Cap?

As of today, Cellectis market cap is 194.02M.

What Is Cellectis's Earnings Per Share (TTM)?

The Cellectis EPS (TTM) is -0.62.

When Is the Next Cellectis Earnings Date?

Cellectis will release its next earnings report on 03 Aug 2025.

From a Technical Analysis Perspective, Is CLLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cellectis Stock Split?

Cellectis has split 0 times.

How Many Employees Does Cellectis Have?

Cellectis has 219 employees.

What is the current trading status of Cellectis (CLLS)?

As of 31 Jul 2025, Cellectis (CLLS) is trading at a price of 2.65, with a previous close of 2.67. The stock has fluctuated within a day range of 2.61 to 2.73, while its 52-week range spans from 1.10 to 3.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.